Doramapimod (GMP)
Doramapimod GMP (BIRB 796 GMP) is an orally active inhibitor for p38 MAPK, with IC50s of 38, 65, 200 and 520 nM, for p38α, p38β, p38γ, p38δ. Doramapimod exhibits cytotoxicity and antitumor activity against multiple myeloma, synergizes with multidrug resistance protein 1 (ABCB1) and aurora kinase inhibitor VX680, promoting their antitumor efficacy against oral epidermoid carcinoma and cervical cancer. Doramapimod also exhibits anti-inflammatory activity[1].
Product Specifications
CAS Number
285983-48-4
Product Name Alternative
BIRB 796 (GMP)
UNSPSC
12352005
Target
P38 MAPK
Type
GMP Small Molecules
Related Pathways
MAPK/ERK Pathway
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/doramapimod-gmp.html
Smiles
O=C(NC1=CC(C(C)(C)C)=NN1C2=CC=C(C)C=C2)NC3=C4C=CC=CC4=C(OCCN5CCOCC5)C=C3
Molecular Formula
C31H37N5O3
Molecular Weight
527.66
References & Citations
[1]Cicenas J, et al., JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers (Basel) . 2017 Dec 21;10 (1) :1.
Shipping Conditions
Room temperature
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Isoform
P38α; p38β; p38γ; p38δ
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Nuclear Factor 1 (NFIA) (NM_001134673) Human Recombinant Protein
Clarin 2 (CLRN2) (NM_001079827) Human Over-expression Lysate
